130 filings
Page 3 of 7
8-K
ez2x1
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
iyjc98sga3l5g m4n0s
26 May 22
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
8:12am
8-K
jeilgoileoxucn
25 May 22
Departure of Directors or Certain Officers
5:01pm
8-K
11kkwo
5 May 22
Axcella Reports First Quarter Financial Results and Provides Business Update
7:41am
DEFA14A
h27oo
7 Apr 22
Additional proxy soliciting materials
4:00pm
8-K
8niuyzafz
30 Mar 22
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
8:05am
8-K
mif1f
18 Mar 22
Termination of a Material Definitive Agreement
4:05pm
8-K
tkw6hrvqbh95i28
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
6e4tcxo18b
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
3i5c0 9v932
7 Feb 22
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
4:00pm
8-K
cn5 iekxgci2visq57w
10 Jan 22
Other Events
8:00am
8-K
yyl1dce8
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
yeyy45v1t7lve7etn3tb
10 Nov 21
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
8:08am
8-K
cgy1p p9vtw51a2r
7 Sep 21
Entry into a Material Definitive Agreement
4:16pm
8-K
4irfz
29 Jul 21
Axcella Reports Second Quarter Financial Results and Provides Business Update
7:58am